Scientific Sessions 2024  /  Translational Discovery in Thrombosis and Anti-thrombotic Therapeutics  /  New mechanisms for antiplatelet therapies
Logo

American Heart Association

  21
  0

Final ID:

New mechanisms for antiplatelet therapies

  • Holinstat, Michael  ( University of Michigan , Ann Arbor , Michigan , United States )
    • Author Disclosures:
    Michael Holinstat: DO have relevant financial relationships ; Consultant:Veralox Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Cereno Scientific:Past (completed) ; Royalties/Patent Beneficiary:Cereno Scientific:Active (exists now) ; Consultant:Cereno Scientific:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Translational Discovery in Thrombosis and Anti-thrombotic Therapeutics

Saturday, 11/16/2024 , 03:15PM - 04:30PM

Abstract Oral Session

More abstracts on this topic:
Sustained Anti-Thrombotic Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential

Stanger Livia, Flores Mariane, Yalavarthi Pooja, Dahlof Bjorn, Holinstat Michael

Building Nucleic Acid-Based Hirudins：Potent, Selective, and Reversible Protease Inhibitors

Yu Haixiang, Yan Amy, Pitoc George, Garber Susannah, Clancy Jeffrey, Sullenger Bruce

More abstracts from these authors:
Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and Thrombosis

Stanger Livia, Rickenberg Andrew, Yalavarthi Pooja, Flores Mariane, Yamaguchi Adriana, Pitt Bertram, Holinstat Michael

Sustained Anti-Thrombotic Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential

Stanger Livia, Flores Mariane, Yalavarthi Pooja, Dahlof Bjorn, Holinstat Michael

You have to be authorized to contact abstract author. Please, Login
Not Available